The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis

Molecular Pharmacology

Volumn 84, Issue 6, 2013, Pages 888-898

  Rousseau, Erwann ^a   Michel, Patrick P ^a   Hirsch, Etienne C ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CALCIUM ION; DOPAMINE; FOCAL ADHESION KINASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LACTOFERRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOROTRITHIOIC ACID TRIBUTYL ESTER; PROTEIN KINASE B; PROTEOHEPARAN SULFATE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CELL LOSS; CELL MATURATION; CELL POPULATION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; EMBRYO; ENDOPLASMIC RETICULUM; ENZYME INACTIVATION; HUMAN; IRON BINDING CAPACITY; MESENCEPHALON; MICROGLIA; MITOCHONDRIAL CALCIUM HOMEOSTASIS; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RAT; SIGNAL TRANSDUCTION;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BINDING SITES; CALCIUM; CELL DEATH; CELLS, CULTURED; DOPAMINE; FOCAL ADHESION KINASE 1; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HOMEOSTASIS; HUMANS; LACTOFERRIN; MESENCEPHALON; MITOCHONDRIA; NERVE DEGENERATION; NEUROGLIA; NEURONS; PARKINSON DISEASE; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 84888878250     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087965     Document Type: Article

References (51)

1. Brock JH (2002) The physiology of lactoferrin. Biochem Cell Biol 80 :1-6.
2. Brookes PS, Yoon Y, Robotham JL, AndersMW, and Sheu SS (2004) Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 287:C817-C833.
3. Calì T, Ottolini D, Negro A, and Brini M (2012) α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J Biol Chem 287:17914-17929.
4. Dauer W and Przedborski S (2003) Parkinson' s disease: mechanisms and models. Neuron 39:889-909.
5. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
6. Drago-Serrano ME, de la Garza-Amaya M, Luna JS, and Campos- Rodríguez R (2012) Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol 12:1-9.
7. Duchen MR (2000) Mitochondria and calcium: from cell signalling to cell death. J Physiol 529:57-68.
8. Faucheux BA, Nillesse N, Damier P, Spik G, Mouatt-Prigent A, Pierce A, Leveugle B, Kubis N, Hauw JJ, and Agid Y et al. (1995) Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 92:9603-9607.
9. Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaïssa M, and Pierce A (2001) Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res 96 :103-113.
10. García-Montoya IA, Cendón TS, Arévalo-Gallegos S, and Rascón-Cruz Q (2012) Lactoferrin a multiple bioactive protein: an overview. Biochim Biophys Acta 1820: 226-236.
11. Grau AJ, Willig V, Fogel W, and Werle E (2001) Assessment of plasma lactoferrin in Parkinson's disease. Mov Disord 16:131-134.
12. Guerreiro S, Toulorge D, Hirsch E, Marien M, Sokoloff P, and Michel PP (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol Pharmacol 74:980-989.
13. Guerreiro S, Ponceau A, Toulorge D, Martin E, Alvarez-Fischer D, Hirsch EC, and Michel PP (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J Neurochem 109:1118-1128.
14. He XB, Yi SH, Rhee YH, Kim H, Han YM, Lee SH, Lee H, Park CH, Lee YS, and Richardson E et al. (2011) Prolonged membrane depolarization enhances midbrain dopamine neuron differentiation via epigenetic histone modifications. Stem Cells 29:1861-1873.
15. Hehlgans S, Haase M, and Cordes N (2007) Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180.
16. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, and Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56:446-451.
17. Hirsch EC and Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397.
18. Hirsch EC, Jenner P, and Przedborski S (2013) Pathogenesis of Parkinson's disease. Mov Disord 28:24-30.
19. Höglinger GU, Carrard G, Michel PP, Medja F, Lombès A, Ruberg M, Friguet B, and Hirsch EC (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86:1297-1307.
20. Jameson GB, Anderson BF, Norris GE, Thomas DH, and Baker EN (1998) Structure of human apolactoferrin at 2.0 A resolution. Refinement and analysis of ligand-induced conformational change. Acta Crystallogr D Biol Crystallogr 54 :1319-1335.
21. Kanwar YS and Sun L (2008) Shuttling of calcium between endoplasmic reticulum and mitochondria in the renal vasculature. Am J Physiol Renal Physiol 295: F1301-F1302.
22. Kettenmann H, Hanisch UK, Noda M, and Verkhratsky A (2011) Physiology of microglia. Physiol Rev 91:461-553.
23. Khan MT, Wagner L, 2nd, Yule DI, Bhanumathy C, and Joseph SK (2006) Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J Biol Chem 281: 3731-3737.
24. Kim JJ, Choi YM, Hong MA, Hwang SS, Yoon SH, Chae SJ, Jee BC, Ku SY, Kim JG, and Moon SY (2009) Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome. Hum Reprod 24:1184-1190.
25. Kruzel ML, Bacsi A, Choudhury B, Sur S, and Boldogh I (2006) Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. Immunology 119:159-166.
26. Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G, and Jiang C (2011) Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS ONE 6:e23710.
27. Levay PF and Viljoen M (1995) Lactoferrin: a general review. Haematologica 80: 252-267.
28. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, Agid Y, and Hof PR (1996) Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol 91:566-572.
29. Lotharius J, Dugan LL, and O'Malley KL (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 19: 1284-1293.
30. Metz-Boutigue MH, Jollès J, Mazurier J, Schoentgen F, Legrand D, Spik G, Montreuil J, and Jollès P (1984) Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur J Biochem 145:659-676.
31. Michel PP, Toulorge D, Guerreiro S, and Hirsch EC (2013) Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. FASEB J 27:3414-3423.
32. Moon C, Han JR, Park HJ, Hah JS, and Kang JL (2009) Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res 10:18.
33. Mourlevat S, Troadec JD, Ruberg M, and Michel PP (2003) Prevention of dopaminergic neuronal death by cyclic AMP in mixed neuronal/glial mesencephalic cultures requires the repression of presumptive astrocytes. Mol Pharmacol 64: 578-586.
34. Muriel MP, Lambeng N, Darios F, Michel PP, Hirsch EC, Agid Y, and Ruberg M (2000) Mitochondrial free calcium levels (Rhod-2 fluorescence) and ultrastructural alterations in neuronally differentiated PC12 cells during ceramide-dependent cell death. J Comp Neurol 426:297-315.
35. Okazaki Y, Kono I, Kuriki T, Funahashi S, Fushimi S, Iqbal M, Okada S, and Toyokuni S (2012) Bovine lactoferrin ameliorates ferric nitrilotriacetate- induced renal oxidative damage in rats. J Clin Biochem Nutr 51:84-90.
36. Orth M and Schapira AH (2002) Mitochondrial involvement in Parkinson's disease. Neurochem Int 40:533-541.
37. Pierce A, Legrand D, and Mazurier J (2009) [Lactoferrin: a multifunctional protein]. Med Sci (Paris) 25:361-369.
38. Ries V, Cheng HC, Baohan A, Kareva T, Oo TF, Rzhetskaya M, Bland RJ, During MJ, Kholodilov N, and Burke RE (2009) Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B. J Neurochem 110:23-33.
39. Sakamoto K, Ito Y, Mori T, and Sugimura K (2006) Interaction of human lactoferrin with cell adhesion molecules through RGD motif elucidated by lactoferrin-binding epitopes. J Biol Chem 281:24472-24478.
40. Salthun-Lassalle B, Hirsch EC, Wolfart J, Ruberg M, and Michel PP (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltagegated sodium channels. J Neurosci 24:5922-5930.
41. Sarrazin S, Lamanna WC, and Esko JD (2011) Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3:a004952.
42. Sun X, Jiang R, Przepiorski A, Reddy S, Palmano KP, and Krissansen GW (2012) "Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. BMC Cancer 12:591.
43. Suzuki YA, Lopez V, and Lönnerdal B (2005) Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 62:2560-2575.
44. Thorne RG, Lakkaraju A, Rodriguez-Boulan E, and Nicholson C (2008) In vivo diffusion of lactoferrin in brain extracellular space is regulated by interactions with heparan sulfate. Proc Natl Acad Sci USA 105:8416-8421.
45. Toulorge D, Guerreiro S, Hirsch EC, and Michel PP (2010) KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis. J Neurochem 114:553-564.
46. Toulorge D, Guerreiro S, Hild A, Maskos U, Hirsch EC, and Michel PP (2011) Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J 25:2563-2573.
47. Traver S, Marien M, Martin E, Hirsch EC, and Michel PP (2006) The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 70:30-40.
48. Tung YT, Chen HL, Yen CC, Lee PY, Tsai HC, Lin MF, and Chen CM (2013) Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. J Dairy Sci 96:2095-2106.
49. Wally J and Buchanan SK (2007) A structural comparison of human serum transferrin and human lactoferrin. Biometals 20:249-262.
50. Ward PP and Conneely OM (2004) Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 17:203-208.
51. Zemann N, Klein P, Wetzel E, Huettinger F, and Huettinger M (2010) Lactoferrin induces growth arrest and nuclear accumulation of Smad-2 in HeLa cells. Biochimie 92:880-884.